Eurofarma announces the extension of the partnership with the Korean Dong-A to 17 countries in Latin America The company will launch an exclusive and novel treatment for diabetes and erectile dysfunction, in Brazil and another 16 countries in the region São Paulo, August 2015 - Eurofarma, a Brazilian pharmaceutical company present in 15 countries in Latin America, announces the partnership with the South Korean laboratory Dong-A, for the clinical development and marketing of the novel oral drug evogliptin, aimed for the treatment of patients with diabetes. The agreement, which at first ensured the development and marketing of the new drug in Brazil, was extended to another 17 countries in Latin America, including Mexico, and was signed at Dong-A's headquarters in Seoul, with the presence of the CEOs Chan-il Park, from Dong-A, and Maurizio Billi, from Eurofarma, in addition to the main executives of both companies. In the country, the drug is expected to be available in 2021. "We are pleased to extend this partnership with Eurofarma to South and Central Americas and Mexico, in addition to Brazil", says Chan-il Park, Dong-A ST's CEO. "Considering that Eurofarma is one of the leaders in medical prescription and that it keeps expanding its sales in Latin America, this is an excellent opportunity for Dong-A to export its technology and new drugs to all the region", completes the executive.
On his turn, Maurizio Billi, Eurofarma's president, reveals: "We intend to expand our partnership with focus in the development of novel products in Brazil and Latin America". The preliminary results of evogliptin study, already in phase III, were disclosed and proved efficacy and safety of the new molecule, showing better glycemic control and reduced rate of adverse effects, such hypoglycemia e weight gain. Another benefit is the dose adjustment waiver in patients with renal failure, common in diabetic patients, and lower drug interaction rate in relation to other drugs with the same mechanism of action. Preliminary data also show signs of renal protection effect, but this benefit must be proven in study to be conducted in Brazil, expected to begin still in 2015.
According to IMS data, the pharmaceutical market in Latin America, turned over about US$ 71 billion in 2014 and keeps growing significantly each year. According to Reuters, today, drug for diabetes turn over US$ 41 billion worldwide. Evogliptin is a new anti-diabetic drug of the DPP4 inhibitors class, which market shall reach increasingly significant participation over the next years. The partnership will also ensure marketing of Zydena® in Latin America, a novel molecule for the treatment of erectile dysfunction which active ingredient, udenafil, from the phosphodiesterase 5 inhibitors class, has exclusive properties: action duration of up to 15 hours, allowing greater comfort of the dosing regimen, and further action selectivity, providing the drug with better safety profile, with lower risk of visual changes and muscle pain.
With the partnership, Eurofarma consolidates its commitment with innovation and welfare, through drugs with new technologies and less adverse effects. In addition to research and development, the company also has investments in education and culture, through Instituto Eurofarma and the sponsorship for dozens of cultural projects, local and international, which have already turned over more than R$15 million so far. Eurofarma is also recognized as one of the pharmaceutical companies with greater environmental responsibility in capturing and using natural resources.
About Eurofarma Eurofarma Group is the first Brazilian multinational pharmaceutical company, with 100% national capital and 43 years of existence, recognized by the medical community and by the society for promoting access to health and quality of life with treatments at a fair price, quality and innovation. Recognized in Brazil and abroad, it has an outstanding market position by acting in the sectors of Medical Prescription, OTC, Generics, Hospitals, Bids, Oncology, Services to Third Parties and Veterinary.
With a portfolio of over 200 products and 200 million units sold only in Brazil, it is already present in 15 countries: Argentina, Belize, Bolivia, Chile, Colombia, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama, Peru, Dominican Republic and Uruguay. Considered one of the best companies to work according to GPTW, it has over 5900 employees, being 2200 representatives, the biggest medical advertisement force in the country. With an average growth of 18% in the last 12 years, in 2014 it has reached an income of R$ 2.6 billion and 6% of the net sales in Research & Development.
Help employers find you! Check out all the jobs and post your resume.
On his turn, Maurizio Billi, Eurofarma's president, reveals: "We intend to expand our partnership with focus in the development of novel products in Brazil and Latin America". The preliminary results of evogliptin study, already in phase III, were disclosed and proved efficacy and safety of the new molecule, showing better glycemic control and reduced rate of adverse effects, such hypoglycemia e weight gain. Another benefit is the dose adjustment waiver in patients with renal failure, common in diabetic patients, and lower drug interaction rate in relation to other drugs with the same mechanism of action. Preliminary data also show signs of renal protection effect, but this benefit must be proven in study to be conducted in Brazil, expected to begin still in 2015.
According to IMS data, the pharmaceutical market in Latin America, turned over about US$ 71 billion in 2014 and keeps growing significantly each year. According to Reuters, today, drug for diabetes turn over US$ 41 billion worldwide. Evogliptin is a new anti-diabetic drug of the DPP4 inhibitors class, which market shall reach increasingly significant participation over the next years. The partnership will also ensure marketing of Zydena® in Latin America, a novel molecule for the treatment of erectile dysfunction which active ingredient, udenafil, from the phosphodiesterase 5 inhibitors class, has exclusive properties: action duration of up to 15 hours, allowing greater comfort of the dosing regimen, and further action selectivity, providing the drug with better safety profile, with lower risk of visual changes and muscle pain.
With the partnership, Eurofarma consolidates its commitment with innovation and welfare, through drugs with new technologies and less adverse effects. In addition to research and development, the company also has investments in education and culture, through Instituto Eurofarma and the sponsorship for dozens of cultural projects, local and international, which have already turned over more than R$15 million so far. Eurofarma is also recognized as one of the pharmaceutical companies with greater environmental responsibility in capturing and using natural resources.
About Eurofarma Eurofarma Group is the first Brazilian multinational pharmaceutical company, with 100% national capital and 43 years of existence, recognized by the medical community and by the society for promoting access to health and quality of life with treatments at a fair price, quality and innovation. Recognized in Brazil and abroad, it has an outstanding market position by acting in the sectors of Medical Prescription, OTC, Generics, Hospitals, Bids, Oncology, Services to Third Parties and Veterinary.
With a portfolio of over 200 products and 200 million units sold only in Brazil, it is already present in 15 countries: Argentina, Belize, Bolivia, Chile, Colombia, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama, Peru, Dominican Republic and Uruguay. Considered one of the best companies to work according to GPTW, it has over 5900 employees, being 2200 representatives, the biggest medical advertisement force in the country. With an average growth of 18% in the last 12 years, in 2014 it has reached an income of R$ 2.6 billion and 6% of the net sales in Research & Development.
Help employers find you! Check out all the jobs and post your resume.
